IdentificationGeneric Name(1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINEDrugBank Accession NumberDB07107BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE (DB07107)× CloseWeightAverage: 370.447 Monoisotopic: 370.179361346 Chemical FormulaC23H22N4OSynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUcAMP-dependent protein kinase catalytic subunit alphaNot AvailableHumansUcAMP-dependent protein kinase inhibitor alphaNot AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.KingdomOrganic compoundsSuper ClassOrganoheterocyclic compoundsClassIndoles and derivativesSub ClassIndolesDirect Parent3-alkylindolesAlternative ParentsAralkylamines / Alkyl aryl ethers / Substituted pyrroles / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivativesSubstituents3-alkylindole / Alkyl aryl ether / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Ether / Heteroaromatic compound / Hydrocarbon derivativeMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeySGHXFHRRWFLILP-XJDXJNMNSA-NInChIInChI=1S/C23H22N4O/c24-20(12-19-14-27-23-4-2-1-3-22(19)23)16-28-21-11-18(13-26-15-21)6-5-17-7-9-25-10-8-17/h1-11,13-15,20,27H,12,16,24H2/b6-5+/t20-/m0/s1IUPAC Name(2S)-1-(1H-indol-3-yl)-3-({5-[(1E)-2-(pyridin-4-yl)ethenyl]pyridin-3-yl}oxy)propan-2-amineSMILES[H][C@@](N)(COC1=CN=CC(\C=C\C2=CC=NC=C2)=C1)CC1=CNC2=C1C=CC=C2ReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound6914613PubChem Substance99443578ChemSpider5290493BindingDB15022ChEMBLCHEMBL383541ZINCZINC000014957382PDBe Ligand4EAPDB Entries2f7xClinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.000753 mg/mLALOGPSlogP3.12ALOGPSlogP3.09ChemaxonlogS-5.7ALOGPSpKa (Strongest Acidic)17.11ChemaxonpKa (Strongest Basic)9.24ChemaxonPhysiological Charge1ChemaxonHydrogen Acceptor Count4ChemaxonHydrogen Donor Count2ChemaxonPolar Surface Area76.82 Å2ChemaxonRotatable Bond Count7ChemaxonRefractivity111.74 m3·mol-1ChemaxonPolarizability41.8 Å3ChemaxonNumber of Rings4ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleYesChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+1.0Blood Brain Barrier+0.9876Caco-2 permeable-0.6341P-glycoprotein substrateSubstrate0.5567P-glycoprotein inhibitor INon-inhibitor0.9097P-glycoprotein inhibitor IINon-inhibitor0.5991Renal organic cation transporterInhibitor0.5CYP450 2C9 substrateNon-substrate0.8584CYP450 2D6 substrateNon-substrate0.6492CYP450 3A4 substrateNon-substrate0.6141CYP450 1A2 substrateInhibitor0.8983CYP450 2C9 inhibitorNon-inhibitor0.6688CYP450 2D6 inhibitorInhibitor0.882CYP450 2C19 inhibitorNon-inhibitor0.5205CYP450 3A4 inhibitorInhibitor0.5933CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9013Ames testNon AMES toxic0.6412CarcinogenicityNon-carcinogens0.961BiodegradationNot ready biodegradable0.997Rat acute toxicity2.5676 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.9059hERG inhibition (predictor II)Non-inhibitor0.6195  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn more


 Details1. cAMP-dependent protein kinase catalytic subunit alphaKindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionUbiquitin protein ligase bindingSpecific FunctionPhosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which bin...Gene NamePRKACAUniprot IDP17612Uniprot NamecAMP-dependent protein kinase catalytic subunit alphaMolecular Weight40589.38 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] 


 Details2. cAMP-dependent protein kinase inhibitor alphaKindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionProtein kinase a catalytic subunit bindingSpecific FunctionExtremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulato...Gene NamePKIAUniprot IDP61925Uniprot NamecAMP-dependent protein kinase inhibitor alphaMolecular Weight7988.435 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:18 / Updated at June 12, 2020 16:52 